Peggy Scherle
Net worth: 1 M $ as of 30/06/2026
Net worth: 1 M $ as of 30/06/2026
Peggy Scherle is Chief Scientific Officer of Prelude Therapeutics, Inc. In her past career she held the position of Vice President-Preclinical Pharmacology at Incyte Corp. She received a doctorate from the University of Pennsylvania and an undergraduate degree from Michigan State University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 27/04/2026 | 190,685 ( 0.29% ) | 1 M $ | 30/06/2026 |
| Companies | Position | Start |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Chief Tech/Sci/R&D Officer | 01/04/2018 |
| Companies | Position | End |
|---|---|---|
| INCYTE CORPORATION | Corporate Officer/Principal | 01/03/2018 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 4 |
|---|---|
Incyte Corp.
Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
Michigan State University
Michigan State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prelude Therapeutics, Inc.
Prelude Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines targeting chromatin function to treat cancer and rare diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions